Key result
Continuous extrapleural ropivacaine infusion leads to toxic plasma concentrations in ~25% of patients.
Why the study?
The pharmacokinetics, dose proportionality, and risk of toxic plasma concentrations of continuous extrapleural ropivacaine 0.2% infusion at different rates after cardiovascular surgery required evaluation.
Does continuous extrapleural infusion of ropivacaine 0.2% at 6 or 9 mL/h result in toxic plasma concentrations in adults undergoing cardiovascular surgery via lateral thoracotomy?
RCT (n=17)
Open-label
Randomized
No
Does continuous extrapleural infusion of ropivacaine 0.2% at 6 or 9 mL/h result in toxic plasma concentrations in adults undergoing cardiovascular surgery via lateral thoracotomy?
Continuous extrapleural infusion of ropivacaine 0.2% at 6 or 9 mL/h after cardiovascular surgery can lead to unpredictable and potentially toxic plasma concentrations.
Answers are grounded in this paper and cite their sources.
Requires caution with continuous extrapleural ropivacaine post-thoracotomy; challenges presumed safety and dose proportionality of standard regimens.
Objective The pharmacokinetics of ropivacaine 0.2% were evaluated during a 48-hour continuous extrapleural infusion with 2 different infusion rates in patients undergoing cardiovascular surgery. The hypotheses that no toxic plasma concentrations of ropivacaine would be reached and that proportionality exists among plasma concentrations and dosage used were tested. Design A prospective, randomized, nonblinded study. Setting The investigation was performed as a single-center study in the Division of Cardiovascular Anesthesia, University Hospital of Zurich, in Switzerland. Participants Seventeen consenting adults scheduled for elective cardiovascular surgery, with or without extracorporeal bypass, via the lateral thoracotomy approach were enrolled. Interventions For postoperative pain relief, patients were randomly assigned to receive continuous extrapleural infusion of ropivacaine 0.2% at a rate of either 6 or 9 mL/h over 48 hours. Measurements and main results Plasma concentrations of ropivacaine reached toxic levels (>2.2 mg/L) in 25% of cases. No proportionality of plasma concentrations of ropivacaine existed when the 2 dosing regimens were compared. Conclusions Plasma concentrations of ropivacaine, administered at the given dose and rates during continuous extrapleural infusion, are unpredictable and may reach toxic levels in patients undergoing major cardiothoracic surgery.
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2007) conducted an RCT in Postoperative pain after cardiovascular surgery via lateral thoracotomy (n=17). Continuous extrapleural infusion of ropivacaine 0.2% vs. Continuous extrapleural infusion of ropivacaine 0.2% at 6 mL/h was evaluated on Toxic plasma concentrations of ropivacaine (>2.2 mg/L) and dose-concentration proportionality. Continuous extrapleural infusion of ropivacaine 0.2% at 6 or 9 mL/h resulted in toxic plasma concentrations in 25% of cases without dose proportionality.
Synapse has enriched 10 related papers. Consider them for comparative context: